EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prophylactic vs. Intermediate Tinzaparin Dosage for the Thromboprophylaxis of Acutely Ill Medical Patients at High Risk of Venous Thromboembolism

Karolina Akinosoglou iD, Stamatia Tsoupra, Ioannis Chandroulis, Eleni Polyzou, Vasiliki Dimakopoulou, Konstantinos Moulakakis iD, Angelos Perperis iD, Eleni Karlafti iD, Elvira Ztriva iD, Vasileios Patriarcheas iD, Periklis Davlouros, Georgia Kaiafa und 1 weitere

Medical Sciences · 2025

DOI: 10.3390/medsci13040291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Sciences, 2025. Verfasst von Karolina Akinosoglou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Patras, 26504 Rio, Greece. Hauptthemen laut MEDLINE: Tinzaparin, Venous Thromboembolism, Fibrinolytic Agents. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Venous thromboembolism (VTE) is the third most common cardiovascular condition, with higher rates among hospitalized patients. The limited efficacy of universal prophylaxis strategies has led to individual VTE risk assessments approaches. The main objective of this study was to assess outcomes in high-risk patients for VTE who receive prophylactic vs. intermediate, weight-adjusted doses of tinzaparin for thromboprophylaxis.

Methods

This was a retrospective study assessing adult patients hospitalized with acute medical disease in a tertiary university hospital from January 2022–2024. Patients were included if found to be at high risk for VTE—as this reflected in Padua Prediction Score (PPS) ≥ 4—and received prophylactic versus intermediate dosage of tinzaparin. Data were collected from patients’ files and analyzed using appropriate statistical methods.

Results

In total, 286 patients were included, of whom 160 received prophylactic and 126 intermediate tinzaparin dosage. The groups were comparable, except for arterial thrombosis history, central venous catheter presence, and median PPS. Patients receiving prophylactic doses exhibited significantly higher mortality rates (20.62 vs. 7.14, p = 0.002), increased length of stay (LOS) (6 vs. 4, p < 0.001), and prolonged treatment durations (5 vs. 3, p = 0.003) compared to patients receiving intermediate dosages. Univariate analysis revealed significant associations between mortality and tinzaparin dose (OR = 3.38, p = 0.002), age (OR = 1.03, p = 0.017), LOS (OR = 1.07, p = 0.001), PPS (OR = 1.62, p < 0.001), Charlson Comorbidity Index (CCI) (OR = 1.27, p < 0.001), and prior thrombotic events (OR = 2.27, p = 0.028). In multivariate analysis, tinzaparin dose (OR = 2.58, p = 0.035), age (OR = 1.04, p = 0.033), LOS (OR = 1.10, p < 0.001), and PPS (OR = 1.33, p = 0.038) remained independent predictors of mortality.

Conclusions

These findings reveal that intermediate tinzaparin dosing is a more effective and safe approach in high-risk for VTE hospitalized patients, emphasizing the need for personalized VTE management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TinzaparinVenous ThromboembolismFibrinolytic AgentsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedRisk FactorsAcute DiseaseLength of StayAdult

Stichwörter der Autor:innen

intensified prophylaxisintermediate dosageprophylactic dosagethromboembolic eventstinzaparinvenous thromboembolism

Substanzen

TinzaparinFibrinolytic Agents

Autor:innen und Institutionen

  • Department of Medicine, University of Patras, 26504 Rio, Greece.
  • Department of Internal Medicine, University General Hospital of Patras, 26504 Rio, Greece.
  • Division of Infectious Diseases, University General Hospital of Patras, 26504 Rio, Greece.
  • School of Social Sciences, Hellenic Open University, 26331 Patra, Greece.
  • Department of Vascular Surgery, University General Hospital "Attikon", 12462 Chaidari, Greece.
  • Division of Cardiology, University General Hospital of Patras, 26504 Rio, Greece.

ORCID-Profile: Karolina Akinosoglou, Konstantinos Moulakakis, Angelos Perperis, Eleni Karlafti, Elvira Ztriva, Vasileios Patriarcheas

Zitieren

APA

Akinosoglou, K., Tsoupra, S., Chandroulis, I., Polyzou, E., Dimakopoulou, V., Moulakakis, K., Perperis, A., Karlafti, E., Ztriva, E., Patriarcheas, V., Davlouros, P., Kaiafa, G., & Savopoulos, C. (2025). Prophylactic vs. Intermediate Tinzaparin Dosage for the Thromboprophylaxis of Acutely Ill Medical Patients at High Risk of Venous Thromboembolism. Medical Sciences. https://doi.org/10.3390/medsci13040291

Vancouver

Akinosoglou K, Tsoupra S, Chandroulis I, Polyzou E, Dimakopoulou V, Moulakakis K, et al. Prophylactic vs. Intermediate Tinzaparin Dosage for the Thromboprophylaxis of Acutely Ill Medical Patients at High Risk of Venous Thromboembolism. Medical Sciences. 2025. doi:10.3390/medsci13040291

BibTeX
@article{Akinosoglou2025,
  author = {Akinosoglou, Karolina and Tsoupra, Stamatia and Chandroulis, Ioannis and Polyzou, Eleni and Dimakopoulou, Vasiliki and Moulakakis, Konstantinos and Perperis, Angelos and Karlafti, Eleni and Ztriva, Elvira and Patriarcheas, Vasileios and Davlouros, Periklis and Kaiafa, Georgia and Savopoulos, Christos},
  title = {Prophylactic vs. Intermediate Tinzaparin Dosage for the Thromboprophylaxis of Acutely Ill Medical Patients at High Risk of Venous Thromboembolism},
  journal = {Medical Sciences},
  year = {2025},
  doi = {10.3390/medsci13040291}
}
Kostenlos starten →